Profile picture

Doctor Maria Estela Tettamanti

Alexander Fleming Institute, Buenos Aires (Argentina)
Follow
Biography
I am a clinical cardiologist. Since 2003 I moved towards the Heart Failure field: first as a Fellow Physician at Favaloro Foundation in Argentina. Later I worked on my PhD research project and thesis in Spain. From 2010 to 2014 I headed the HF and PH Unit at Austral University Hospital, ARG. I have a strong interest in the genetic aetiologies of cardiomyopathies. I completed a Master in Molecular Genetics (UBA, ARG). In 2016 I got an International Master in PH (Menendez Pelayo University, Spain) and in May 2018, the HFA of the ESC Certification in HF. Nowadays I act as a cardio - oncologist at Fleming Institute (BA, ARG). As part of a team of cardiologists, I follow up and treat patients with ventricular dysfunction associated to their cancer treatment. I am especially interested in research directed to the better understanding of the molecular and genetic issues of this entity, because its results will improve our knowledge on the subject and offer new possible solutions for patients.
Logo ESC

Contributor content

Sensitivity and specificity of strain rate for the early detection of left ventricular dysfunction in breast cancer patients receiving adjuvant treatment with adriamycin with or without trastuzumab
Presentation
Sensitivity and specificity of strain rate for the early detection of left ventricular dysfunction in breast cancer patients receiving adjuvant treatment with adriamycin with or without trastuzumab
Cardiac transplantation after oncologic diseases: a case of cardiotoxic cardiomyopathy.
Presentation
Cardiac transplantation after oncologic diseases: a case of cardiotoxic cardiomyopathy.
Early detection of cardiotoxicity in breast cancer patients: red flags according to a traffic lights - like coding system after long-term experience at a referral centre
Presentation
Early detection of cardiotoxicity in breast cancer patients: red flags according to a traffic lights - like coding system after long-term experience at a referral centre
Trastuzumab associated cardiotoxicity in breast cancer patients: a report after 4 years of follow up at a specialized centre
Presentation
Trastuzumab associated cardiotoxicity in breast cancer patients: a report after 4 years of follow up at a specialized centre

ESC 365 is supported by